Showing 7851-7860 of 9757 results for "".
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- Increased Cost Diminishes Sunscreen Use: Reporthttps://practicaldermatology.com/news/cost-influences-sunscreen-use-raising-skin-cancer-risk-study-shows/2474206/Patients use less sunscreen when it’s more expensive, according to a brief report in the Journal of the American Academy of Dermatology. Researchers from the University of California, Sa
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Melanoma Risk Model Validated in Global Studyhttps://practicaldermatology.com/news/international-study-strengthens-confidence-in-sentinel-node-prediction-tool/2474126/The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator has been validated in a large, multinational cohort, reinforcing its applicability across diverse populations and clinical settings. The MIA
- Study: Dermabrasion Trials Rarely Report Race or Skin Typehttps://practicaldermatology.com/news/study-dermabrasion-trials-rarely-report-race-or-skin-type/2474005/Most clinical trials studying dermabrasion have failed to report racial or skin-type demographics, according to a new systematic review. "Clinical trials that are racially homogenous or do not report race limit the generalizab
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late